Post-Topotecan Mixed Response and 'Redifferentiation-akin' Phenomenon on Dual Tracer PET-CT in Multiple Treatment-Resistant Metastatic Neuroendocrine Neoplasm.
68 Ga-DOTATATE
PET-CT
neuroendocrine neoplasm
peptide receptor radionuclide therapy
topotecan
Journal
World journal of nuclear medicine
ISSN: 1450-1147
Titre abrégé: World J Nucl Med
Pays: Germany
ID NLM: 101286955
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
medline:
24
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
A 50-year-old female patient of heavily pre-treated (chemotherapy and multiple treatment-resistant) and progressive intermediate-grade metastatic neuroendocrine neoplasm is presented, wherein the lesions showed mixed response following topotecan treatment and multiple hepatic metastasis showed increase in the SSTR expression and decrease in FDG concentration on dual-tracer PET/CT (
Identifiants
pubmed: 37223630
doi: 10.1055/s-0043-1760761
pii: 22100002
pmc: PMC10202582
doi:
Types de publication
Case Reports
Langues
eng
Pagination
130-134Informations de copyright
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).
Déclaration de conflit d'intérêts
Conflict of Interest None declared.
Références
Exp Ther Med. 2021 Oct;22(4):1179
pubmed: 34475969
Nucl Med Commun. 2016 Jun;37(6):669-71
pubmed: 27105440
Cancer Med. 2016 Sep;5(9):2261-7
pubmed: 27456539
Endocr Relat Cancer. 2013 Aug 19;20(5):649-57
pubmed: 23845449
J Cancer. 2014 Aug 01;5(8):628-32
pubmed: 25157273
J Nucl Med Technol. 2020 Sep;48(3):290-291
pubmed: 32111657